In patients with DM ( n = 3623 ) , vorapaxar significantly reduced the primary end point ( 11.4 % versus 14.3 % ; hazard ratio , 0.73 [ 95 % confidence interval , 0.60-0 .89 ] ; P = 0.002 ) with a number needed to treat to avoid 1 major cardiovascular event of 29 .